eligibility_summary
Adults with advanced solid tumors. Escalation: any refractory/intolerant tumor. Expansion: NSCLC (PD-L1 tested/tissue available), MSS/pMMR CRC after ≥2 lines without active liver mets, or HCC after ≥1 line. Need measurable disease, ECOG 0–1/0–2, >12-week survival, adequate organ function, neg pregnancy/contraception. Exclude recent trial/therapy/major surgery, prior CTLA-4 failure, active CNS disease, CV/autoimmune/infectious disease, immunosuppression, effusions, bleeding/clot risk, HIV/HBV/HCV, live vaccine ≤4 wks, severe mAb allergy, substance abuse, pregnancy/lactation, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 trial of dual immune checkpoint blockade: BAT4706 + BAT1308. BAT4706 is an Fc-glycosylated, fully humanized anti-CTLA-4 monoclonal antibody (immune checkpoint inhibitor). It blocks CTLA-4 on T cells—especially regulatory T cells (Tregs)—to enhance CD28-mediated costimulation and T-cell priming, Fc glycosylation may promote Treg depletion via ADCC/CDC in tumors. BAT1308 is a recombinant humanized anti–PD-1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD-1 on exhausted effector T cells, preventing PD-L1/PD-L2–mediated inhibition and reinvigorating cytotoxic function. Targets/cells/pathways: CTLA-4/CD28 axis in lymphoid tissues, PD-1/PD-L1 pathway in the tumor microenvironment, CD8+ and CD4+ T cells, Tregs, and APC–T-cell interactions. Intended synergy: improved T-cell priming plus effector function. IV Q3W combination for 4 cycles, then BAT1308 maintenance, escalation and expansion in NSCLC, MSS CRC, and HCC.